Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Endocrine 2Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Multiple Myeloma 449Neoplasms, Plasma Cell 69Lymphoma, Mantle-Cell 66Recurrence 65Lymphoma 65Lymphoma, Non-Hodgkin 43Lymphoma, Follicular 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 36Lymphoma, Large B-Cell, Diffuse 34Waldenstrom Macroglobulinemia 33Lymphoma, B-Cell, Marginal Zone 30Leukemia, Lymphocytic, Chronic, B-Cell 28Neoplasms 24Immunoglobulin Light-chain Amyloidosis 24Carcinoma, Non-Small-Cell Lung 24Leukemia 21Hodgkin Disease 17Hematologic Neoplasms 16Lymphoma, B-Cell 14Burkitt Lymphoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 13Lymphoma, Large-Cell, Anaplastic 13Immunoblastic Lymphadenopathy 12Breast Neoplasms 12Mycosis Fungoides 11Lymphoma, T-Cell, Cutaneous 11Lymphoma, Large-Cell, Immunoblastic 11Congenital Abnormalities 11

Interventions

Iodine-131 21lenvatinib 17Magnetic Resonance Spectroscopy 17trametinib 13Sorafenib 13Thyrotropin Alfa 12pembrolizumab 11dabrafenib 11Thyroidectomy 10Surgical Procedures, Operative 10Thyroxine 9Paclitaxel 9vandetanib 8selpercatinib 8Sunitinib 7Nivolumab 7Fluorodeoxyglucose F18 7cabozantinib 6anlotinib 6Everolimus 6Biopsy 6pazopanib 5Vemurafenib 5Triiodothyronine 5Specimen Handling 5Saline Solution 5Radiotherapy 5Radiofrequency Ablation 5Iodine-124 5Cyclophosphamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Bortezomib × Clear all
NCT00104871 2018-12-19

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

National Cancer Institute (NCI)

Phase 2 Completed
24 enrolled 6 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT00923247 2018-11-29

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
22 enrolled 21 charts
Head & Neck

Neoplasms, Thyroid Neoplasms, Carcinoma, Medullary

NCT00667641 2011-05-10

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Rutgers, The State University of New Jersey

Phase 1 Completed
16 enrolled
BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Ovarian Epithelial, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡